New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
10:20 EDTENT, TROX, EVHC, CROX, CPWR, HZNP, CTSH, GDP, AUXL, ONVOHigh option volume stocks
High option volume stocks: ONVO EVHC AUXL HZNP TROX GDP CPWR ENT CTSH CROX
News For ONVO;EVHC;AUXL;HZNP;TROX;GDP;CPWR;ENT;CTSH;CROX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 28, 2014
09:32 EDTGDPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:26 EDTGDPGoodrich Petroleum downgraded to Sector Perform from Outperform at Iberia
Subscribe for More Information
November 26, 2014
15:37 EDTGDPGoodrich Petroleum December volatility elevated at 118
Subscribe for More Information
November 24, 2014
10:13 EDTENTGlobal Eagle management to meet with Piper Jaffray
Subscribe for More Information
November 21, 2014
09:04 EDTCTSHImmigration reform to have modest impact on IT services stocks, says Bernstein
Subscribe for More Information
08:35 EDTAUXLBioSpecifics announces new data on XIAFLEX for Peyronie's Disease
Subscribe for More Information
November 20, 2014
07:09 EDTAUXLAuxilium presents STENDRA data at SMSNA meeting
Auxilium Pharmaceuticals announced that data were presented regarding the use of STENDRA tablets for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. A post-hoc analysis of data from a placebo-controlled, Phase 4 study of STENDRA evaluated men who had at least one attempt at intercourse within approximately 15 minutes of taking the medication. The STENDRA 100 and 200mg doses demonstrated statistically significant improvement in onset of erectogenic effect at approximately 15 minutes compared to placebo, with a mean per-patient proportion of sexual attempts that resulted in at least one successful intercourse within approximately 15 minutes after dosing of 73.3% and 71.5%, respectively. Results of a study examining the proportion of men with ED who reported successful intercourse within the first three doses of STENDRA showed more than 60% of patients reported successful intercourse within the first three doses of STENDRA. This compares to about 40% with placebo. A higher percentage, or 75% for STENDRA vs. 56% for placebo, also reported success after any dose.
07:07 EDTAUXLAuxilium presents XIAFLEX for Peyronie's Disease data
Auxilium Pharmaceuticals announced presentations of data from new studies, as well as new analyses of data from the Phase 2 and the pivotal Phase 3 IMPRESS trials evaluating XIAFLEX for the treatment of Peyronie's disease, at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. Data were presented providing further evidence that PD bother is clinically significant and may be a useful measure in clinical practice when treating PD. Data were also presented suggesting that improvements in PD bother are correlated with improvements in penile curvature deformity.
06:23 EDTGDPStocks with implied volatility movement; CLF GDP
Stocks with implied volatility movement; Cliffs Natural (CLF) 110, Goodrich Petroleum (GDP) 144 according to iVolatility.
November 19, 2014
17:40 EDTCPWRCompuware to sell Detroit building, sees charge of $110M-$115M during Q3
Compuware disclosed in a filing that on November 17, Compuware entered into an agreement for the sale of its headquarters facility located at One Campus Martius, Detroit, Michigan, to 1000 Webward , a Delaware limited liability company for approximately $142M in cash. The closing of the transaction will occur on December 31. Based on the plan of action to dispose of the Building, the company will record a non-cash pre-tax impairment charge of $110M to $115M during Q315.
07:33 EDTAUXLEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
12:08 EDTONVOOn The Fly: Midday Wrap
Subscribe for More Information
10:15 EDTCTSHHigh option volume stocks
Subscribe for More Information
08:09 EDTONVOOrganovo announces commercial release of exVive3D liver tissue
Organovo Holdings announced the full commercial release of the exVive3D Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.
07:36 EDTCTSHUBS to hold a conference
Global Technology Conference to be held in Sausalito, California on November 18-20 with webcasted company presentations to begin on November 18 at 10:45 am; not all company presentations may be webcasted. Webcast Link
07:02 EDTAUXLAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information
November 17, 2014
11:11 EDTCPWRHigh option volume stocks:
Subscribe for More Information
07:10 EDTGDPGlobal Hunter Securities to hold a conference
Annual 1x1 San Francisco Energy Day is being held in San Francisco on November 17.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use